Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer intensifies. This is up from the$8.5bn that Novo offered last week when it submitted its initial, unexpected, “unsolicited” offer. This offer shook the pharma sector after it seemed that Pfizer’s $7.3bn offer to take over Metsera was all but certain. Under the most recent proposal, Novo Nordisk would acquire all outstanding shares of Metsera’s common stock at a price of$62.20 per share in cash, eq ...